Cassava Sciences Inc (SAVA)
22.30
0.00 (0.00%)
USD |
NASDAQ |
Apr 30, 12:50
Cassava Sciences SG&A Expense (Quarterly): 4.058M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 4.058M |
September 30, 2023 | 4.276M |
June 30, 2023 | 3.808M |
March 31, 2023 | 4.392M |
December 31, 2022 | 3.285M |
September 30, 2022 | 2.819M |
June 30, 2022 | 2.969M |
March 31, 2022 | 2.915M |
December 31, 2021 | 4.102M |
September 30, 2021 | 1.712M |
June 30, 2021 | 1.237M |
March 31, 2021 | 1.004M |
December 31, 2020 | 1.105M |
September 30, 2020 | 1.038M |
June 30, 2020 | 0.818M |
March 31, 2020 | 0.778M |
December 31, 2019 | 0.838M |
September 30, 2019 | 0.831M |
June 30, 2019 | 0.845M |
March 31, 2019 | 0.877M |
December 31, 2018 | 0.748M |
September 30, 2018 | 0.848M |
June 30, 2018 | 0.998M |
March 31, 2018 | 1.099M |
December 31, 2017 | 0.879M |
Date | Value |
---|---|
September 30, 2017 | 0.977M |
June 30, 2017 | 1.103M |
March 31, 2017 | 1.376M |
December 31, 2016 | 1.208M |
September 30, 2016 | 0.884M |
June 30, 2016 | 1.455M |
March 31, 2016 | 2.234M |
December 31, 2015 | 0.914M |
September 30, 2015 | 1.33M |
June 30, 2015 | 1.401M |
March 31, 2015 | 1.457M |
December 31, 2014 | 1.059M |
September 30, 2014 | 1.429M |
June 30, 2014 | 1.322M |
March 31, 2014 | 1.317M |
December 31, 2013 | 1.19M |
September 30, 2013 | 1.29M |
June 30, 2013 | 1.139M |
March 31, 2013 | 1.218M |
December 31, 2012 | 2.207M |
September 30, 2012 | 2.001M |
June 30, 2012 | 1.461M |
March 31, 2012 | 1.512M |
December 31, 2011 | 1.62M |
September 30, 2011 | 1.753M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.778M
Minimum
Mar 2020
4.392M
Maximum
Mar 2023
2.254M
Average
1.712M
Median
Sep 2021
SG&A Expense (Quarterly) Benchmarks
Amylyx Pharmaceuticals Inc | 52.24M |
Clearside Biomedical Inc | 2.947M |
Lantern Pharma Inc | 1.304M |
NovaBay Pharmaceuticals Inc | 2.609M |
Palatin Technologies Inc | 3.033M |